CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 90 enrolled
Drug / intervention
Gemcitabine and Pazopanib +1 moredrug
Likely dose
Gemcitabine and Pazopanib 1000 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01593748
NCT01593748Phase 2Completed
CompareCT.gov

A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma

Medical University of South Carolina·interventional·Posted May 8, 2012·Updated Apr 6, 2020

In Brief

A Phase 2 clinical trial evaluating Gemcitabine and Pazopanib and Gemcitabine and Docetaxel for Sarcoma. Completed, enrolled 90 participants across 8 sites.

Detailed Summary

This study is for adult subjects with advanced tissue sarcoma. The study involves the drugs Pazopanib (Votrient), Gemcitabine (Gemzar), and Docetaxel (Taxotere). The purpose of this study is to test the effectiveness and safety of Gemcitabine and Pazopanib compared with Gemcitabine and Docetaxel in participants with soft tissue sarcoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 8, 2012
Enrollment StartSep 27, 2012
Primary CompletionApr 24, 2019
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 14.2 years ago

Interventions

Gemcitabine and Pazopanibdrug

Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.

Gemcitabine and Docetaxeldrug

Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.